Four-year-old Apartim Dey Singha of Kolkata was treated through stem cell transplant for Attention Deficit Hyperactive Disorder, Autism, at the Duke University Clinical Trial for treatment of Autism through autologous (own stem cells) cord blood stem cell transplants.
Autistic kids have difficulty in expressing themselves and their inability can be clearly noticed by the parent or the caretaker. It is the third most common developmental disorder in which, according to experts, one in 166 children are affected in India. Structural damage to the brain, toxins, pollutants and environmental related and genetic metabolic are few of the most common causes associated with Autism.
Early diagnosis, coupled with swift and effective intervention, is paramount to achieving the best possible prognosis for the child. In recent times, stem cell transplant has emerged as a new treatment option for Autism.
Mayur Abhaya, CEO, MD, lifeCell says: “It’s heartwarming to see clinical improvement and development milestones in Apartim. Scientists at Duke University have published results of their study which indicates improvement in autistic children post infusion of autologous umbilical cord stem cells and this improvement has further validated the high quality preservation standards of stem cells at lifeCell. There are many ongoing clinical trials across the world and this certainly gives hope to parents who have preserved their baby’s stem cells at birth”.